Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
ASH Highlights on NK cells: a new frontier for cancer immunotherapy
March 7, 2024
Dr Evren Alici, principal researcher and head of the cell and gene therapy group at the Karolinska Institute in Stockholm, Sweden was so kind to summarise data on NK cell
Efficacy of Brexu-cel in the treatment of high risk R/R MCL patients
January 8, 2024
In this presentation, data sourced from the CIBM-TR registry were utilized to assess the differential outcomes of Brexu-cel therapy in patients with R/R MCL exhibiting high-risk features, such as delTP53/17P,
Patient-Reported Outcomes in the QuANTUM-First Trial: Quizartinib Versus Standard Chemotherapy in FLT3-ITD AML patients
January 4, 2024
At the ASH meeting, Professor Oliva presented the patient-reported outcomes from the QuANTUM-First trial, a phase 3 clinical investigation assessing the efficacy and safety of quizartinib. Quizartinib, is approved in
ASH Highlights on Multiple Myeloma
December 12, 2023
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, was so kind to share his highlights on multiple myeloma from
Health related QoL data of KarMMa-3
December 12, 2023
KarMMa-3 constitutes an open-label, phase 3 randomized clinical trial aimed at investigating the efficacy of a single infusion of the BCMA-targeting CAR-T cell product ide-cel in comparison to conventional standard-of-care
Pros and cons of emerging therapeutic targets in multiple myeloma
December 12, 2023
Dr Rutger Callens, a haematologist at AZ Delta in Roeselare, delved into the intricacies of emerging therapeutic targets in multiple myeloma (MM), weighing the pros and cons associated with these
Pirtobrutinib in relapsed/refractory MCL patients: update from the BRUIN trial
December 12, 2023
BTKi has demonstrated efficacy in MCL; however, a substantial number of patients experience relapse during treatment. Pirtobrutinib, a non-covalent third-generation BTKi, exhibits enhanced effectiveness in the post-covalent BTKi setting and
IsKia trial: results of Isa-KRd in transplant-eligible NDMM patients
December 11, 2023
Dr Annemiek Broijl, haematologist at the Erasmus MC hospital in Rotterdam, the Netherlands and co-principal investigator of the IsKia study was so kind to present the results. The study aims
In-depth stories
ASH Highlights on NK cells: a new frontier for cancer immunotherapy
March 7, 2024
Dr Evren Alici, principal researcher and head of the cell and gene therapy group at the Karolinska Institute in Stockholm, Sweden was so kind to summarise data on NK cell
Efficacy of Brexu-cel in the treatment of high risk R/R MCL patients
January 8, 2024
In this presentation, data sourced from the CIBM-TR registry were utilized to assess the differential outcomes of Brexu-cel therapy in patients with R/R MCL exhibiting high-risk features, such as delTP53/17P,
Patient-Reported Outcomes in the QuANTUM-First Trial: Quizartinib Versus Standard Chemotherapy in FLT3-ITD AML patients
January 4, 2024
At the ASH meeting, Professor Oliva presented the patient-reported outcomes from the QuANTUM-First trial, a phase 3 clinical investigation assessing the efficacy and safety of quizartinib. Quizartinib, is approved in
ASH Highlights on Multiple Myeloma
December 12, 2023
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, was so kind to share his highlights on multiple myeloma from
Health related QoL data of KarMMa-3
December 12, 2023
KarMMa-3 constitutes an open-label, phase 3 randomized clinical trial aimed at investigating the efficacy of a single infusion of the BCMA-targeting CAR-T cell product ide-cel in comparison to conventional standard-of-care
Pros and cons of emerging therapeutic targets in multiple myeloma
December 12, 2023
Dr Rutger Callens, a haematologist at AZ Delta in Roeselare, delved into the intricacies of emerging therapeutic targets in multiple myeloma (MM), weighing the pros and cons associated with these
Pirtobrutinib in relapsed/refractory MCL patients: update from the BRUIN trial
December 12, 2023
BTKi has demonstrated efficacy in MCL; however, a substantial number of patients experience relapse during treatment. Pirtobrutinib, a non-covalent third-generation BTKi, exhibits enhanced effectiveness in the post-covalent BTKi setting and
IsKia trial: results of Isa-KRd in transplant-eligible NDMM patients
December 11, 2023
Dr Annemiek Broijl, haematologist at the Erasmus MC hospital in Rotterdam, the Netherlands and co-principal investigator of the IsKia study was so kind to present the results. The study aims
Poster selection
The Impact of Isatuximab HGG in R/R MM patients
December 13, 2023
Dr Cesar Rodriguez, affiliated with Mount Sinai in New York, presents a research study examining the impact of isatuximab (Isa) on the occurrence of hypogammaglobulinemia (HGG) and the concomitant risk
AML real world evidence initiative: venetoclax versus control in patients unfit for intensive chemotherapy
December 13, 2023
In this study, Dr Aaron Goldberg from the Memorial Sloan Kettering Cancer Center presents a comparative analysis of outcomes and healthcare research utilization in patients with AML treated with venetoclax
ELEVATE-TN: Impact of first-year dose modifications in treatment-naive CLL patients treated with acalabrutinib
December 13, 2023
Prof George Follows, a consulting haematologist from Nuffield Health Cambridge Hospital, presents a post-hoc analysis of the ELEVATE-TN trial, a prospective, randomized study involving treatment-naïve elderly CLL patients. Patients were
cfDNA as alternative to bone marrow cells for molecular diagnostics and MM monitoring
December 13, 2023
In this presentation, Dory Abelman, a PhD candidate at the Princess Margaret Cancer Centre, University of Toronto, assesses the concordance of molecular profiles between cancer cells derived from bone marrow
The SKylaRK trial
December 13, 2023
Dr Betsy O’Donnell, a haematologist at the Dana-Farber Cancer Institute (US), presents the findings from the SKylaRK trial, a phase 2 study in NDMM patients eligible for transplantation, who received
Pragmatic recommendations for treating patients with myelofibrosis, particularly those experiencing cytopenias
December 12, 2023
Prof Claire Harrison, a haematologist at Guy’s and St. Thomas’ Hospital in London (UK), presents collaborative efforts involving colleagues and patients to offer pragmatic recommendations for treating patients with myelofibrosis,
The REMNANT study: will treatment at MRD relapse improve survival in MM?
December 12, 2023
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway outlined the REMNANT study.
The REMNANT study aims to assess whether addressing MRD relapses
First results of a Lysa study from the French Descar-T registry
December 12, 2023
Dr Gabriel Brisou presents preliminary findings on the utilization of axi-cel in the second-line treatment of patients with early R/R LBCL. In France, real-world data encompassing all patients subjected to